Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerAdvances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapyReversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use.Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
P2860
Q26738703-9256ABFA-9DAE-420F-9B31-8224E0120F40Q28829239-9A4ED7BE-C5C7-4D65-97C0-66EACCB75BB9Q37463725-F0F95DC4-00DB-4695-973D-35E69E3956BBQ37735587-49697867-E328-418C-999F-10C63E7E1BB0Q38618888-37ADD333-1919-4295-8932-764BED7B2639Q38756919-596B289D-7AB2-4148-AF5A-735EC13FC644Q38813222-30CD682B-2370-40D1-9C20-C66A02D81B37Q38917844-67F0BE92-4D78-42FD-BE80-7889E8B9A37BQ39063642-4B2A7E59-C3BA-4685-A58C-58C887BF96ACQ39487974-9513E406-1E8B-44CD-84C2-715AD4F05E62Q39612278-E89BD943-7C33-4770-9BA5-9AD4F36BB7F3Q50055627-87E9F0B9-DA73-46AF-9465-86ECEBA7C895
P2860
Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Treatment evolution for metast ...... ve analysis of real-world data
@ast
Treatment evolution for metast ...... ve analysis of real-world data
@en
type
label
Treatment evolution for metast ...... ve analysis of real-world data
@ast
Treatment evolution for metast ...... ve analysis of real-world data
@en
prefLabel
Treatment evolution for metast ...... ve analysis of real-world data
@ast
Treatment evolution for metast ...... ve analysis of real-world data
@en
P2093
P2860
P356
P1433
P1476
Treatment evolution for metast ...... ve analysis of real-world data
@en
P2093
Maneesha Mehra
Mary B Todd
Ravi C Potluri
Thomas W Flaig
P2860
P304
P356
10.1002/CAM4.576
P407
P577
2015-12-29T00:00:00Z